Figure 2.

Evolution of renin–angiotensin system (RAS) inhibition strategies and their duration of action.

Note: Therapies included in blue are currently available in the clinic, while those in red are in only available in clinical trials or under development. This figure shows the typical duration of action of the various drug classes; however, some drugs will have longer or shorter durations of action than the typical value given in this figure. For example, some ACE inhibitors will have a longer duration of action than hours and are dosed daily, while some AT₂ agonists may have a halflife of hours and require frequent dosing. It is thought the duration of action for these new therapies is likely to be longer than the action of currently available therapies.

ACE, angiotensin converting enzyme; AT₁, angiotensin II type 1; AT₂; angiotensin II type 2; RAS, renin–angiotensin system.